In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives

Journal of Infection and Chemotherapy

Volumn 21, Issue 2, 2015, Pages 114-117

  Rizek, Camila ^a   Ferraz, Juliana Rosa ^a   van der Heijden, Inneke Marie ^a   Giudice, Mauro ^a   Mostachio, Anna Karina ^a   Paez, Jorge ^a   Carrilho, Claudia ^b   Levin, Anna Sara ^a   Costa, Silvia F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b University Hospital of University of Londrina   (Brazil)

Author keywords

Fosfomycin; MDR gram negatives; Minocycline; Polymyxin B; Tigecycline

Indexed keywords

CARBAPENEM DERIVATIVE; COTRIMOXAZOLE; FOSFOMYCIN; LEVOFLOXACIN; MINOCYCLINE; POLYMYXIN B; SULTAMICILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER; ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BROTH DILUTION; GENETIC RESISTANCE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FOSFOMYCIN; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POLYMYXIN B;

EID: 84928331455     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.10.009     Document Type: Article

References (31)

1. Livermore D.M. Has the era of untreatable infections arrived?. JAntimicrob Chemother 2009, 64:i29-36.
2. Paksu M.S., Paksu S., Karadag A., Sensoy G., Asilioglu N., Yildizdas D., et al. Old agent, new experience: colistin use in the paediatric intensive care unit-a multicentre study. Int J Antimicrob Agents 2012, 40:140-144.
3. Czihal P., Knappe D., Fritsche S., Zahn M., Berthold N., Piantavigna S., et al. Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant gram-negative pathogens. ACS Chem Biol 2012, 20:1281-1291.
4. Cho Y.S., Yim H., Yang H.T., Hur J., Chun W., Kim J.H., et al. Use of parenteral colistin for the treatment of multiresistant gram-negative organisms in major burn patients in South Korea. Infection 2012, 40:27-33.
5. Ku K., Pogue J.M., Moshos J., Bheemreddy S., Wang Y., Bhargava A., et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 2012, 40:983-987.
6. Brooke J.S. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012, 25:2-41.
7. Hu L.F., Chang X., Ye Y., Wang Z.X., Shao Y.B., Shi W., et al. Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 2011, 37:230-234.
8. Fusté E., Galisteo G.J., Jover L., Vinuesa T., Villa T.G., Viñas M. Comparison of antibiotic susceptibility of old and current Serratia. Future Microbiol 2012, 7:781-786.
9. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) CLSI 2013, Clinical and Laboratory Standards Institute, Wayne, PA.
10. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0 (2013) 2013, EUCAST, Available at:, [accessed 18.04.12]. http://www.eucast.org/clinical_breakpoints/.
11. FDA. U.S. Food and Drug Administration. Tygacil (tigecycline) for injection. [accessed 18.04.12]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm228387.htm.
12. FDA. U.S. Food and Drug Administration. Tygacil (tigecycline) iv injection label. [accessed 18.04.12]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf.
13. Lin L., Ling B.D., Li X.Z. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Int J Antimicrob Agents 2009, 33:27-32.
14. Woodford N., Ellington M.J., Coelho J.M., Turton J.F., Ward M.E., Brown S., et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006, 27:351-353.
15. Chen Y., Zhou Z., Jiang Y., Yu Y. Emergence of NDM-1-producing Acinetobacter baumannii in China. JAntimicrob Chemother 2011, 66:1255-1259.
16. Higgins P.G., Poirel L., Lehmann M., Nordmann P., Seifert H. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrobial Agents Chemother 2009, 53:5035-5038.
17. Mendes R.E., Kiyota K.A., Monteiro J., Castanheira M., Andrade S.S., Gales A.C., et al. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. JClin Microbiol 2007, 45:544-547.
18. Mostachio A.K., Levin A.S., Rizek C., Rossi F., Zerbini J., Costa S.F. High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil. Int J Antimicrob Agents 2012, 39:396-401.
19. Toleman M.A., Bennett P.M., Walsh T.R. ISCR elements: novel gene-capturing systems of the 21st century?. Microbiol Mol Biol Rev 2006, 70:296-316.
20. Sánchez M.B., Hernández A., Rodríguez-Martínez J.M., Martínez-Martínez L., Martínez J.L. Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of QNR determinants. BMC Microbiol 2008, 8:148.
21. Gales A.C., Jones R.N., Sader H.S. Contemporary activity of colistin and polymyxin B against a worldwide collection of gram-negative pathogens: results from the SENTRY antimicrobial surveillance program (2006-09). JAntimicrob Chemother 2011, 66:2070-2074.
22. Lim T.P., Tan T.Y., Lee W., Sasikala S., Tan T.T., Hsu L.Y., et al. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 2011, 6:e18485.
23. Nicodemo A.C., Araujo M.R., Ruiz A.S., Gales A.C. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. JAntimicrob Chemother 2004, 53:604-608.
24. Livermore D.M., Warner M., Mushtaq S., Doumith M., Zhang J., Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011, 37:415-419.
25. Ahmed N.H., Baba K., Clay C., Lekalakala R., Hoosen A.A. In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa. BMC Res Notes 2012, 3:215.
26. Liao C.H., Kung H.C., Hsu G.J., Lu P.L., Liu Y.C., Chen C.M., et al. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Int J Antimicrob Agents 2008, 32:192-196.
27. Rumbo C., Gato E., López M., Ruiz de Alegría C., Fernández-Cuenca F,Martínez-Martínez L., Vila J., et al. Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrobial Agents Chemother 2013, 57:5247-5257.
28. Behera B., Das A., Mathur P., Kapil A., Gadepalli R., Dhawan B. Tigecycline susceptibility report from an Indian tertiary care hospital. Indian J Med Res 2009, 129:446-450.
29. Karageorgopoulos D.E., Wang R., Yu X.H., Falagas M.E. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens. JAntimicrob Chemother 2012, 67:255-268.
30. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10:43-50.
31. Perdigão-Neto L.V., Oliveira M.S., Rizek C.F., Carrilho C.M., Costa S.F., Levin A.S. Susceptibility to fosfomycin of multiresistant gram-negative bacteria and performance of different susceptibility testing methods: preparing for clinical use. Antimicrobial Agents Chemother 2013, 57.